


RETRACTION NOTE

Retraction Note: Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer

Donge Tang, Jiayi He, Yong Dai, Xinyan Geng, Qixin Leng, Haowu Jiang, Rui Sun and Songhui Xu 

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2023

Cancer Gene Therapy (2023) 30:1442; <https://doi.org/10.1038/s41417-023-00669-0>

Retraction Note to: *Cancer Gene Therapy* <https://doi.org/10.1038/s41417-021-00332-6>, published online 14 April 2021

The Editor-in-Chief has retracted this article because it contains material that substantially overlaps with the following article [1]. Qixin Leng, Xinyan Geng, Jiayi He, Haowu Jiang and Rui Sun have informed the journal that they were not involved in this article or aware of its submission.

Qixin Leng, Xinyan Geng, Jiayi He, Haowu Jiang and Rui Sun agree to this retraction. Songhui Xu does not agree to this retraction, or

the wording of the retraction. Donge Tang and Yong Dai have not responded to any correspondence from the editor/publisher about this retraction.

REFERENCE

1. Tang D-E, Dai Y, He J-X, Lin L-W, Leng Q-X, Geng X-Y, et al. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer. *J Pathol.* 2020;252:101–13.e5495. <https://doi.org/10.1002/path.5495>.